Literature DB >> 8587855

Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal.

C Riesenman1.   

Abstract

Evaluation of the inhibitory effects of antidepressant drugs on hepatic cytochrome P450 isoenzymes can allow clinicians to predict drug interactions occurring via this mechanism a priori. The magnitude and clinical relevance of these drug interactions are dependent on many factors including concentration of the isoenzyme inhibitor, contribution of active metabolites with isoenzyme inhibitory activity, and toxicity of the concomitant medication. This review summarizes information to date regarding the inhibitory potency of fluoxetine, fluvoxamine, paroxetine, sertraline, nefazodone, and venlafaxine on five isoenzyme systems: CYP2D6, CYP3A3/4, CYP1A2, CYP2C9, and CYP2C19. Both in vitro and in vivo isoenzyme inhibition data are presented and correlated to drug interactions of clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587855

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

1.  Second-generation antihistamines: a comparative review.

Authors:  J W Slater; A D Zechnich; D G Haxby
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 2.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

4.  Human immunodeficiency virus and depression in primary care: a clinical review.

Authors:  Tiziano Colibazzi; Teresa T Hsu; William S Gilmer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 5.  Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.

Authors:  S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.

Authors:  J Andrew Skirvin; Stuart M Lichtman
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 7.  Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management.

Authors:  Mohamed Naguib; Robert Koorn
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 8.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Authors:  R H Foster; K L Goa
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

Review 10.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.